Ono Pharmaceutical has expanded its collaboration with Congruence Therapeutics to leverage Congruence’s Revenir™ platform for the discovery of small molecule modulators in neurology and immunology, in addition to their ongoing work in oncology. Under this new agreement, Ono will secure exclusive global rights for the development and commercialization of these drug candidates, along with providing upfront payments and milestone incentives. This partnership aims to accelerate drug development for patients with unmet medical needs, showcasing both companies’ commitment to innovation in biotechnology.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/ono-pharma-announces-new-drug-discovery-collaboration-with-congruence-therapeutics-in-the-priority-areas-of-neurology-and-immunology
